Stay updated with breaking news from Refractive Surgery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
IHEEZO Represents the First Approved Use in the U.S. Ophthalmic Market of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic Approved for the U.S. Ophthalmic Market in Nearly
Most of us will never need a transplant, but for the people who do, transplants can be lifesaving. ...
/PRNewswire/ -- Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative...
IHEEZO Represents the First Approved Use in the U.S. Ophthalmic Market of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic Approved for the U.S. Ophthalmic Market in Nearly 14 Years
RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for inherited...